Analysis of the domestic market price of ensifentrine-Ohtuvayre and its differences across regions

Ensifentrine (Ensifentrine), trade nameOhtuvayre, is the first treatment for chronic obstructive pulmonary disease (COPD) is an inhaled dual phosphodiesterase inhibitor (PDE3/PDE4inhibitor) for maintenance treatment. Its mechanism of action is to improve airway function through smooth muscle relaxation and anti-inflammatory effects, and improve the patient's breathing comfort. The drug has been approved by the FDA in the United States for long-term management of COPD symptoms, improving patients' quality of life while reducing the risk of acute exacerbations.

In the domestic market, Ohtuvayre has not yet been launched and has not been included in the medical insurance system. Therefore, patients in mainland China cannot purchase it through formal channels and need to wait for drug approval and marketing before they can obtain it. Since medicines are not included in medical insurance, there is currently no local pricing basis for their costs, and there are certain restrictions on their use.

In the Hong Kong market, the price of Ohtuvayre 3mg/2.5mL (60 doses) is about 44,500 Hong Kong dollars, which is equivalent to about 39,000 yuan in RMB. The price is higher and it imposes a greater financial burden on patients, so it is recommended to use it rationally under the guidance of a doctor. If patients consider purchasing through Hong Kong pharmacies, they should pay attention to the formality of the channel and the authenticity of the drugs to ensure drug safety.

Overall, Ohtuvayre, as a new maintenance treatment drug for COPD, has a unique dual mechanism of action and shows potential in improving patients' respiratory function and quality of life. However, its accessibility in mainland China is limited. Patients should comprehensively consider drug effectiveness, financial burden, and doctor's advice when choosing treatment options, and continue to pay attention to drug approval and marketing developments to obtain more treatment options in the future.

Reference materials:https://www.drugs.com/